Compare Global X NASDAQ 100 Covered Call ETF (QYLD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X NASDAQ 100 Covered Call ETF vs Viatris Inc — how do they compare? Global X NASDAQ 100 Covered Call ETF trades at $17.8, while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Viatris Inc pays a 2.73% dividend while Global X NASDAQ 100 Covered Call ETF pays none, and Viatris Inc is trading nearer its 52-week high, Global X NASDAQ 100 Covered Call ETF nearer its low. Which is the better fit depends on your goals.
| QYLD | VTRS | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $18.52 | $17.59 |
52-Week Low | $16.46 | $8.74 |
Market Cap | — | $20.50B |
Enterprise Value | — | $32.71B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QYLD trades at $17.66, down 0.84% with a bearish technical outlook. The ETF shows neutral oscillators but bearish moving averages, with RSI at oversold levels. Recent dividend payments of $0.18-$0.19 highlight its income focus, though news articles question long-term wealth erosion versus Nasdaq growth.
The outlook remains cautious due to covered-call strategy limitations during market rallies. Risks include NAV erosion and underperformance versus benchmarks. Income-focused investors may find value, but growth-oriented investors face significant upside capture constraints in bullish markets.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
